Free Newsletter
| Get the pharma industry's daily monitor, with a special focus on pharmaceutical company news and the market development of FDA approved products. Sign up for free today! |
Tysabri to get new Euro label
The European Medicines Agency called for an update to product information for Biogen Idec and Elan's multiple sclerosis drug Tysabri, highlighting the risk of a potentially deadly brain infection. But the EMEA also confirmed that it still believes the drug's benefits outweigh its risks. EMEA release
Be the first to comment
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
